Cargando…
Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is
Bromodomain and extraterminal (BET) domain inhibitors (BETis) show efficacy on NUT midline carcinoma (NMC). However, not all NMC patients respond, and responders eventually develop resistance and relapse. Using CRISPR and ORF expression screens, we systematically examined the ability of cancer drive...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120715/ https://www.ncbi.nlm.nih.gov/pubmed/30135075 http://dx.doi.org/10.1101/gad.315648.118 |
_version_ | 1783352316374548480 |
---|---|
author | Liao, Sida Maertens, Ophélia Cichowski, Karen Elledge, Stephen J. |
author_facet | Liao, Sida Maertens, Ophélia Cichowski, Karen Elledge, Stephen J. |
author_sort | Liao, Sida |
collection | PubMed |
description | Bromodomain and extraterminal (BET) domain inhibitors (BETis) show efficacy on NUT midline carcinoma (NMC). However, not all NMC patients respond, and responders eventually develop resistance and relapse. Using CRISPR and ORF expression screens, we systematically examined the ability of cancer drivers to mediate resistance of NMC to BETis and uncovered six general classes/pathways mediating resistance. Among these, we showed that RRAS2 attenuated the effect of JQ1 in part by sustaining ERK pathway function during BRD4 inhibition. Furthermore, overexpression of Kruppel-like factor 4 (KLF4), mediated BETi resistance in NMC cells through restoration of the E2F and MYC gene expression program. Finally, we found that expression of cyclin D1 or an oncogenic cyclin D3 mutant or RB1 loss protected NMC cells from BETi-induced cell cycle arrest. Consistent with these findings, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors showed synergistic effects with BETis on NMC in vitro as well as in vivo, thereby establishing a potential two-drug therapy for NMC. |
format | Online Article Text |
id | pubmed-6120715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cold Spring Harbor Laboratory Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61207152019-03-01 Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is Liao, Sida Maertens, Ophélia Cichowski, Karen Elledge, Stephen J. Genes Dev Research Paper Bromodomain and extraterminal (BET) domain inhibitors (BETis) show efficacy on NUT midline carcinoma (NMC). However, not all NMC patients respond, and responders eventually develop resistance and relapse. Using CRISPR and ORF expression screens, we systematically examined the ability of cancer drivers to mediate resistance of NMC to BETis and uncovered six general classes/pathways mediating resistance. Among these, we showed that RRAS2 attenuated the effect of JQ1 in part by sustaining ERK pathway function during BRD4 inhibition. Furthermore, overexpression of Kruppel-like factor 4 (KLF4), mediated BETi resistance in NMC cells through restoration of the E2F and MYC gene expression program. Finally, we found that expression of cyclin D1 or an oncogenic cyclin D3 mutant or RB1 loss protected NMC cells from BETi-induced cell cycle arrest. Consistent with these findings, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors showed synergistic effects with BETis on NMC in vitro as well as in vivo, thereby establishing a potential two-drug therapy for NMC. Cold Spring Harbor Laboratory Press 2018-09-01 /pmc/articles/PMC6120715/ /pubmed/30135075 http://dx.doi.org/10.1101/gad.315648.118 Text en © 2018 Liao et al.; Published by Cold Spring Harbor Laboratory Press http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Research Paper Liao, Sida Maertens, Ophélia Cichowski, Karen Elledge, Stephen J. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is |
title | Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is |
title_full | Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is |
title_fullStr | Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is |
title_full_unstemmed | Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is |
title_short | Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is |
title_sort | genetic modifiers of the brd4-nut dependency of nut midline carcinoma uncovers a synergism between betis and cdk4/6is |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120715/ https://www.ncbi.nlm.nih.gov/pubmed/30135075 http://dx.doi.org/10.1101/gad.315648.118 |
work_keys_str_mv | AT liaosida geneticmodifiersofthebrd4nutdependencyofnutmidlinecarcinomauncoversasynergismbetweenbetisandcdk46is AT maertensophelia geneticmodifiersofthebrd4nutdependencyofnutmidlinecarcinomauncoversasynergismbetweenbetisandcdk46is AT cichowskikaren geneticmodifiersofthebrd4nutdependencyofnutmidlinecarcinomauncoversasynergismbetweenbetisandcdk46is AT elledgestephenj geneticmodifiersofthebrd4nutdependencyofnutmidlinecarcinomauncoversasynergismbetweenbetisandcdk46is |